TCIM
MCRB icon

TIAA CREF Investment Management’s Seres Therapeutics MCRB Stock Holding History

TIAA CREF Investment Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$263K Buy
1,914
+48
+3% +$5.85K ﹤0.01% 2820
2018
Q4 		$169K Sell
1,866
-43
-2% -$6.02K ﹤0.01% 2903
2018
Q3 		$290K Sell
1,909
-647
-25% -$105K ﹤0.01% 2899
2018
Q2 		$440K Sell
2,556
-77
-3% -$12.6K ﹤0.01% 2844
2018
Q1 		$387K Buy
2,633
+85
+3% +$16.3K ﹤0.01% 2844
2017
Q4 		$517K Sell
2,548
-123
-5% -$25.3K ﹤0.01% 2757
2017
Q3 		$857K Hold
2,671
– – ﹤0.01% 2591
2017
Q2 		$604K Sell
2,671
-2,833
-51% -$582K ﹤0.01% 2772
2017
Q1 		$1.24M Buy
5,504
+691
+14% +$140K ﹤0.01% 2407
2016
Q4 		$953K Buy
4,813
+1,004
+26% +$219K ﹤0.01% 2564
2016
Q3 		$936 Buy
3,809
+1,154
+43% +$405K ﹤0.01% 2575
2016
Q2 		$1.54M Buy
2,655
+1,393
+110% +$817K ﹤0.01% 2277
2016
Q1 		$670K Sell
1,262
-11
-0.9% -$5.74K ﹤0.01% 2677
2015
Q4 		$893K Hold
1,273
– – ﹤0.01% 2641
2015
Q3 		$755K Buy
+1,273
New +$1.04M ﹤0.01% 2734

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TIAA CREF Investment Management's MCRB Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Seres Therapeutics (MCRB) stake by 2.6% in Q1 2019, buying an estimated $5.85K and bringing the position to 1,914 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #2820.

TIAA CREF Investment Management first reported a position in MCRB in Q3 2015 and has held it in 15 quarters since. The position peaked at $1.54M in Q2 2016. 82 funds tracked by Wall St. Rank hold MCRB as of Q1 2019.

  • TIAA CREF Investment Management held 1,914 shares of Seres Therapeutics worth $263K as of Q1 2019.
  • TIAA CREF Investment Management bought 48 Seres Therapeutics shares in Q1 2019, an estimated $5.85K.
  • Seres Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2820 holding.
  • TIAA CREF Investment Management first reported a position in Seres Therapeutics in Q3 2015 and has held it in 15 quarters since.
  • TIAA CREF Investment Management's Seres Therapeutics position peaked at $1.54M in Q2 2016.
  • 82 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.